Similar to CDK4/6 inhibitors, small molecule inhibitors of the PI3K/AKT/mTOR pathway are also FDA approved for use in endocrine resistant ER+/HER2-breast cancer in combination with ET. This evidence concerns the gene ERBB2 and breast carcinoma.